The role of topotecan in the treatment of advanced cervical cancer

Gynecologic Oncology

Volumn 90, Issue 3 SUPPL., 2003, Pages

  Fiorica, James V ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cervical cancer; Chemotherapy; Topotecan

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL; PLATINUM; RADIOSENSITIZING AGENT; TOPOTECAN;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; BONE MARROW TOXICITY; BRACHYTHERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; EARLY DIAGNOSIS; EMOTIONAL DISORDER; HUMAN; HYSTERECTOMY; IN VITRO STUDY; LEUKOPENIA; LOW ENERGY RADIATION; LUNG CANCER; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; RECURRENT CANCER; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

EID: 0042733263     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00465-7     Document Type: Conference Paper

References (41)

1. Fiorica J.V. Update on the treatment of cervical and uterine carcinoma focus on topotecan . Oncologist. 7:(suppl 5):2002;36-45.
2. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2:2001;533-543.
3. American Cancer Society. Cancer facts and figures 2002. Available from URL: http://www.cancer.org/downloads/STT/CancerFacts&Figures2002TM.pdf . Accessed 4 July 2003.
4. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK, editors. SEER cancer statistics review, 1975-2000. Bethesda, MD: National Cancer Institute. Available from URL: http://seer.cancer.gov/csr/1975_2000, 2003. Accessed 4 July 2003.
5. Rein D.T., Kurbacher C.M. The role of chemotherapy in invasive cancer of the cervix uteri current standards and future prospects . Anti-Cancer Drugs. 12:2001;787-795.
6. Cannistra S.A., Niloff J.M. Cancer of the uterine cervix. N Engl J Med. 334:1996;1030-1038.
7. Fletcher G.H., Wharton J.T. Principles of irradiation therapy for gynecologic malignancy. Curr Prob Obstet Gynecol. 2:1978;2-44.
8. Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L. 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 340:1999;1154-1161.
9. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1999;1137-1143.
10. Noel G., Mazeron J.J. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. Cisplatin, radiation, and adjuvant hysterectomy for bulky stage Ib cervical carcinoma. Cancer Radiother. 3:1999;345-347.
11. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1999;1144-1153.
12. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C. Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes a Gynecologic Oncology Group and Southwest Oncology Group study . J Clin Oncol. 17:1999;1339-1348.
13. Peters W.A. 3rd, Liu P.Y., Barrett R.J. 2nd, Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 18:2000;1606-1613.
14. Thomas G.M. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med. 340:1999;1198-1200.
15. National Cancer Institute. Concurrent chemoradiation for cervical cancer. Clinical Announcement, Washington DC, Feb 22, 1999.
16. Vermorken J.B. The role of chemotherapy in squamous cell carcinoma of the uterine cervix a review . Int J Gynecol Cancer. 3:1993;129.
17. Abu-Rustum N.R., Lee S., Massad L.S. Topotecan for recurrent cervical cancer after platinum-based therapy. Int J Gynecol Cancer. 10:2000;285-288.
18. Bookman M.A., Blessing J.A., Hanjani P., Herzog T.J., Andersen W.A. Topotecan in squamous cell carcinoma of the cervix a phase II study of the Gynecologic Oncology Group . Gynecol Oncol. 77:2000;446-449.
19. Thigpen T., Shingleton H., Homesley H., Lagasse L., Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix a phase II study of the Gynecologic Oncology Group . Cancer. 48:1981;899-903.
20. Thigpen J.T., Blessing J.A., DiSaia P.J., Fowler W.C. Jr, Hatch K.D. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix a Gynecologic Oncology Group study . Gynecol Oncol. 32:1989;198-202.
21. Bonomi P., Blessing J.A., Stehman F.B., DiSaia P.J., Walton L., Major F.J. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix a Gynecologic Oncology Group study . J Clin Oncol. 3:1985;1079-1085.
22. Alberts D.S., Garcia D., Mason-Liddil N. Cisplatin in advanced cancer of the cervix an update . Semin Oncol. 18:(suppl 3):1991;11-24.
23. Omura G.A., Blessing J.A., Vaccarello L., Berman M.L., Clarke-Pearson D.L., Mutch D.G., et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix a Gynecologic Oncology Group study . J Clin Oncol. 15:1997;165-171.
24. Boabang P., Kurbacher C.M., Kohlhagen H., Waida A., Amo-Takyi B.K. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-tumor chemosensitivity assay. Anticancer Drugs. 11:2000;843-848.
25. Noda K, Sasaki H, Yamamoto K, Yamamoto T, Nishimura R, Sugiyama T, et al. Phase II trial of topotecan for cervical cancer of the uterus. Proc Am Soc Clin Oncol 1996;15:abstract.
26. Muderspach L.I., Blessing J.A., Levenback C., Moore J.L. Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix a Gynecologic Oncology Group study . Gynecol Oncol. 81:2001;213-215.
27. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth a rational approach to clinical protocol design . J Natl Cancer Inst. 86:1994;1517-1524.
28. Fiorica J., Holloway R., Ndubisi B., Orr J., Grendys E., Boothby R., et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 85:2002;89-94.
29. Selleck M., Smith D., Resnik E., Brafman L., Troxel A., Tiersten A. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Proc Am Soc Clin Oncol. 21:2002;A2509.
30. Greimel E., Thiel I., Peintinger F., Cegnar I., Pongratz E. Prospective assessment of quality of life of female cancer patients. Gynecol Oncol. 85:2002;140-147.
31. Kim J.H., Kim S.H., Kolozsvary A., Khil M.S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys. 22:1992;515-518.
32. Boscia R.E., Korbut T., Holden S.A., Ara G., Teicher B.A. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int J Cancer. 53:1993;118-123.
33. Lamond J.P., Wang M., Kinsella T.J., Boothman D.A. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int J Radiat Oncol Biol Phys. 36:1996;361-368.
34. Lamond J.P., Wang M., Kinsella T.J., Boothman D.A. Radiation lethality enhancement with 9-aminocamptothecin comparison to other topoisomerase I inhibitors . Int J Radiat Oncol Biol Phys. 36:1996;369-376.
35. Lamond J.P., Mehta M.P., Boothman D.A. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies report of a synergistic effect between topotecan and radiation . J Neurooncol. 30:1996;1-6.
36. Mareschini R., Colombo A., Caserini C., Perego P., Supino R., Capranico G., et al. Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int J Cancer. 66:1996;342-346.
37. Dunton C.J., King S.A., Neufeld J., Tolosa J., Perez G., Avila A., et al. Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecol Oncol. 85:2002;185-187.
38. Bell M.C., Davidson S.A., Mathis J.M., Ampil F. Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma a phase I trial . Gynecol Oncol. 80:2001;128-131.
39. Morris RT. Weekly topotecan in the management of ovarian cancer Gynecol Oncology 2003;90(3):S34-38.
40. von Pawel J., Gatzemeier U., Pujol J.L., Moreau L., Bildat S., Ranson M., et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 19:2001;1743-1749.
41. GOG-9913 study protocol. Phase I study of extended field radiotherapy, cisplatin, and topotecan in patients with locally advanced cervical cancer. Date first published: 2003-01-26. Study outline available on URL: http://www.cancer.gov/clinicaltrials/view_clinicaltrials.aspx?version= patient&c_drid=270680&clickitem=ClinicalTrialsSearchResult . Accessed 4 July 2003.